Want to see PL:NEU full AI Analyst Report?
Top Page
NEUCA S.A.
(NEU)
Select Model
Select Model
Rating:61Neutral
Price Target:
zł755.00
▼(-10.55% Downside)
Action:N/A
Date:09/16/25
The overall stock score reflects NEUCA S.A.’s steady growth and prudent capital structure, balanced against weak net profitability and recent negative trends in cash flow. Valuation and technical analysis signals are neutral to slightly cautious, reinforcing a moderate risk-reward outlook. There are no new insights from earnings calls or corporate events that would meaningfully alter the risk profile.
Positive Factors
Stable Margins
Stable margins indicate effective cost management and pricing strategies, supporting NEUCA's profitability and operational efficiency over time.
Negative Factors
Earnings Growth
Negative EPS growth reflects challenges in maintaining earnings momentum, which could impact NEUCA's ability to reinvest in its business and sustain shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Stable Margins
Stable margins indicate effective cost management and pricing strategies, supporting NEUCA's profitability and operational efficiency over time.
Read all positive factors
NEUCA S.A. (NEU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
zł3.67B
Dividend Yield2.26%
Average Volume (3M)1.23K
Price to Earnings (P/E)18.3
Beta (1Y)0.50
Revenue Growth8.42%
EPS Growth43.47%
CountryPL
Employees5,004
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)43.08
Shares Outstanding4,642,802
10 Day Avg. Volume1,049
30 Day Avg. Volume1,226
Financial Highlights & Ratios
PEG Ratio-31.55
Price to Book (P/B)3.49
Price to Sales (P/S)0.27
P/FCF Ratio9.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)44.93
Revenue Forecast (FY)zł14.50B
NEUCA S.A. Business Overview & Revenue Model
Company Description
NEUCA S.A., headquartered in Torun, Poland, specializes in supplying pharmaceutical products to pharmacies and healthcare facilities throughout the country. The firm structures its business around distinct segments: wholesale pharmaceutical distri...
How the Company Makes Money
NEUCA generates revenue through several key streams. The primary source of income comes from the wholesale distribution of pharmaceuticals, which involves purchasing drugs from manufacturers and selling them to pharmacies and healthcare facilities...
NEUCA S.A. Financial Statement Overview
Summary
Income Statement
71
Positive
Balance Sheet
76
Positive
Cash Flow
50
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.14B | 13.64B | 12.61B | 11.81B | 11.23B | 9.86B |
| Gross Profit | 1.64B | 1.56B | 1.44B | 1.31B | 1.24B | 1.02B |
| EBITDA | 433.22M | 360.38M | 417.85M | 401.82M | 352.41M | 293.42M |
| Net Income | 196.51M | 155.58M | 154.24M | 146.27M | 137.24M | 150.66M |
Balance Sheet | ||||||
| Total Assets | 6.23B | 6.33B | 5.51B | 5.18B | 4.84B | 4.12B |
| Cash, Cash Equivalents and Short-Term Investments | 137.31M | 168.62M | 143.94M | 119.55M | 225.87M | 89.18M |
| Total Debt | 797.46M | 853.32M | 448.57M | 663.43M | 378.08M | 176.59M |
| Total Liabilities | 4.90B | 5.06B | 4.10B | 4.12B | 3.91B | 3.23B |
| Stockholders Equity | 1.12B | 1.06B | 1.14B | 990.36M | 880.24M | 847.29M |
Cash Flow | ||||||
| Free Cash Flow | 231.35M | 371.66M | -29.68M | 194.09M | 254.49M | 247.45M |
| Operating Cash Flow | 360.91M | 496.54M | 63.23M | 288.27M | 335.94M | 300.20M |
| Investing Cash Flow | -281.59M | -323.45M | -198.10M | -257.03M | -180.22M | -145.49M |
| Financing Cash Flow | -119.54M | -144.95M | 139.62M | -139.09M | -6.64M | -112.76M |
NEUCA S.A. Technical Analysis
Positive
844.00
Price Trends
741.15
Positive
721.14
Positive
740.01
Positive
Market Momentum
8.03
Positive
61.25
Neutral
63.66
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PL:NEU, the sentiment is Positive. The current price of 844 is above the 20-day moving average (MA) of 777.45, above the 50-day MA of 741.15, and above the 200-day MA of 740.01, indicating a bullish trend. The MACD of 8.03 indicates Positive momentum. The RSI at 61.25 is Neutral, neither overbought nor oversold. The STOCH value of 63.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PL:NEU.
NEUCA S.A. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | zł3.67B | 18.31 | 14.63% | 1.95% | 8.42% | 43.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | zł1.20B | 10.83 | 26.07% | ― | ― | ― | |
40 Underperform | zł494.68M | -134.33 | -1.15% | ― | -1.63% | 26.23% | |
37 Underperform | zł424.95M | -4.70 | -135.46% | ― | -15.04% | 24.48% |
* Healthcare Sector Average
PL:NEU
NEUCA S.A.
789.00
156.09
24.66%
PL:RVU
Ryvu Therapeutics SA
18.38
-10.52
-36.40%
PL:SCP
Scope Fluidics SA
136.80
-20.80
-13.20%
PL:VOX
Voxel S.A.
133.20
-32.04
-19.39%
PL:CLN
Celon Pharma SA
22.20
-0.70
-3.06%
PL:SLV
Selvita SA
27.00
-4.10
-13.18%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.